<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="82611">
  <stage>Registered</stage>
  <submitdate>15/02/2008</submitdate>
  <approvaldate>18/02/2008</approvaldate>
  <actrnumber>ACTRN12608000093381</actrnumber>
  <trial_identification>
    <studytitle>A randomized controlled study to compare tension free vaginal tape (TVT) and Monarc trans-obturator tape (TOT) in the treatment of women with urodynamic stress incontinence (USI) and intrinsic sphincter deficiency (ISD).</studytitle>
    <scientifictitle>A randomized controlled study to compare tension free vaginal tape (TVT) and Monarc trans-obturator tape (TOT) in the treatment of women with urodynamic stress incontinence (USI) and intrinsic sphincter deficiency (ISD).</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>Nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Intrinsic sphincter deficiency</healthcondition>
    <healthcondition>Best surgical correction</healthcondition>
    <healthcondition>Urodynamic stress incontinence</healthcondition>
    <conditioncode>
      <conditioncode1>Renal and Urogenital</conditioncode1>
      <conditioncode2>Other renal and urogenital disorders</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Surgery</conditioncode1>
      <conditioncode2>Surgical techniques</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Insertion of tension free vaginal tape (retropubic sling), trans-obturator suburethral sling. Surgery for sling insertion takes 15-20 minutes, theatre session time varies due to commonly performed concommitant prolapse surgery. The study has a 3 year follow up period after surgery was performed.</interventions>
    <comparator>Monarc transobturator tape/tension free vaginal tape 
Both treatments are suburethral sling procedure used in the treatment of stress urinary incontinence. The TVT tension free vaginal tape is the tape procedure that has been used the longest (since 1996) while the obturator tape is a newer technique requiring further evaluation/ and comparison with the established TVT</comparator>
    <control>Active</control>
    <interventioncode>Treatment: surgery</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>subjective cure of urinary incontinence assessed with visual analog score, quality of life questionaires (UDI 6, IIQ 7)</outcome>
      <timepoint>6 months, longterm follow up 3 years post surgery</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>need for repeat surgical treatment</outcome>
      <timepoint>6 months after primary procedure</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>objective cure of urinary incontinence on urodynamics</outcome>
      <timepoint>6 months</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>surgical postoperative complication</outcome>
      <timepoint>first six weeks postoperative</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>longterm surgical complications</outcome>
      <timepoint>6 months, longterm follow up 3 years post surgery</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>surgical intra-operative complication</outcome>
      <timepoint>immediately</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>urodynamics stress incontinence with intrinsic sphincter deficiency</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>pelvic infection, voiding difficulty (defined at cystometry as maximum flow less than 15 mL per second or voiding pressure greater than 50 cm H2O or residual volume greater than 100 mL), inability to give informed consent</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence>computer generated random allocation in a ratio of 1:1 to receiving a TVT or Monarc (TOT) as procedure to treat the incontinence.</sequence>
    <masking>Open (masking not used)</masking>
    <assignment />
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase />
    <anticipatedstartdate>1/02/2004</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>182</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Closed: follow-up continuing</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <postcode>3168</postcode>
    <postcode>3084</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Hospital</primarysponsortype>
    <primarysponsorname>Mercy Hospital for Women</primarysponsorname>
    <primarysponsoraddress>163 Studley Road
Heidelberg 3084
Victoria</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Hospital</fundingtype>
      <fundingname>Mercy Hospital for Women</fundingname>
      <fundingaddress>163 Studley Road
Heidelberg 3084
Victoria</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Hospital</sponsortype>
      <sponsorname>Monash Medical Centre</sponsorname>
      <sponsoraddress>246 Clayton Road 
Clayton 3168
Victoria</sponsoraddress>
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
    <othercollaborator>
      <othercollaboratortype>Hospital</othercollaboratortype>
      <othercollaboratorname>Monash Medical Centre</othercollaboratorname>
      <othercollaboratoraddress>246 Clayton Road 
Clayton 3168
Victoria</othercollaboratoraddress>
      <othercollaboratorcountry>Australia</othercollaboratorcountry>
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>This project will assess the success (cure rate) of two types of suburethral sling procedures in the treatment of women with urodynamic stress incontinence and intrinsic sphincter deficiency. This group of patients has a low urethral closure pressure and is a challenging subgroup of patients that has shown less success in their treatment with other surgical methods (e.g. Burch colposuspension). The suburethral sling procedures (e.g. TVT) have shown better results in this group. The Monarc sling is a new procedure that places the tape in a different way (through the obturator foramen) as the TVT, which has been established for some time in the treatment of intrinsic sphincter deficiency. Therefore we will assess and compare the success and other outcomes (complication rate, hospital stay, etc) of both procedures.</summary>
    <trialwebsite />
    <publication>Effectiveness of tension-free vaginal tape compared with transobturator tape in women with stress urinary incontinence and intrinsic sphincter deficiency: a randomized controlled trial.
Schierlitz L, Dwyer PL, Rosamilia A, Murray C, Thomas E, De Souza A, Lim YN, Hiscock R.
Obstet Gynecol. 2008 Dec;112(6):1253-61.
 
Abstract no.1, Annual scientific meeting IUGA/ICS 2010 Toronto
A RANDOMIZED CONTROLLED STUDY TO COMPARE TENSION FREE VAGINAL TAPE (TVT) AND MONARC TRANS-OBTURATOR TAPE IN THE TREATMENT OF WOMEN WITH URODYNAMIC STRESS INCONTINENCE (USI) AND INTRINSIC SPHINCTER 
DEFICIENCY (ISD): THE THREE YEAR FOLLOW UP.
Schierlitz L, Dwyer P, Rosamilia A, Murray C, Thomas E, Fitzgerald E, Hiscock R, De Souza A
Int Urogynecol J (2010) 21 (Suppl 1):S1S428</publication>
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>The Mercy Health and Age Care Human Research Ethics Commitee</ethicname>
      <ethicaddress>Mercy Hospital for Women
163 Studley Road
Heidelberg 3084
Victoria</ethicaddress>
      <ethicapprovaldate />
      <hrec>04/04</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Southern Health Human Research Ethics Commitee</ethicname>
      <ethicaddress>Monash Medical Centre
246 Clayton Road 
Clayton 3168
Victoria</ethicaddress>
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Lore Schierlitz</name>
      <address>Mercy Hospital for Women
163 Studley Road
Heidelberg 3084
Victoria</address>
      <phone>03 -94161553</phone>
      <fax />
      <email>lschierlitz@mercy.com.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Lore Schierlitz</name>
      <address>Mercy Hospital for Women
163 Studley Road
Heidelberg 3084
Victoria</address>
      <phone>03 -94161553</phone>
      <fax />
      <email>lschierlitz@mercy.com.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Lore Schierlitz</name>
      <address>Mercy Hospital for Women
163 Studley Road
Heidelberg 3084
Victoria</address>
      <phone>03 -94161553</phone>
      <fax />
      <email>lschierlitz@mercy.com.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>